Volume 77, Issue 6_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Despite considerable efforts by multiple governmental and nongovernmental organizations to increase access to artemisinin-based combination therapies (ACTs), these life-saving antimalarial drugs remain largely unaffordable to the most vulnerable populations. The cost of artemisinin derivatives, ACTs’ crucial active ingredients, contributes significantly to the high price of these therapies. With a grant from the Bill and Melinda Gates Foundation, a partnership between Amyris Biotechnologies, the Institute for OneWorld Health, and the University of California, Berkeley is using synthetic biology to help reduce the cost of artemisinin. This article presents a description of the technological platform the partnership—called the Artemisinin Project—is developing to manufacture a low-cost, semi-synthetic artemisinin through a fermentation process. By making life-saving ACTs affordable to the people who most need them, the Artemisinin Project hopes to show that the power of biotechnology can be harnessed to provide solutions to global health problems.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. DiMasi JA, Hansen RW, Grabowski HG, 2003. The price of innovation: new estimates of drug development costs. J Health Econ 22 : 151–185.
    [Google Scholar]
  2. Eline Korenromp JM, Nahlen B, Wardlaw T, Young M, 2005. World Malaria Report: World Health Organization (WHO), Roll Back Malaria (RBM) and United Nations Children’s Fund (UNICEF). Geneva: World Health Organization.
  3. Bloland P, 2001. Drug Resistance in Malaria. A Background Document for the WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva: World Health Organization.
  4. Klayman DL, 1985. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228 : 1049–1055.
    [Google Scholar]
  5. Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GA, 2005. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med 2 : e92.
    [Google Scholar]
  6. Olumese P, 2006. Guidelines for the Treatment of Malaria. Geneva: World Health Organization.
  7. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O, 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366 : 1960–1963.
    [Google Scholar]
  8. Grupper M, 2005. Meeting on the Production of Artemisinin and ACTs. Arusha, Tanzania: DFID Health Resource Centre, Roll Back Malaria, World Health Organization.
  9. Martin VJ, Yoshikuni Y, Keasling JD, 2001. The in vivo synthesis of plant sesquiterpenes by Escherichia coli. Biotechnol Bioeng 75 : 497–503.
    [Google Scholar]
  10. Martin VJ, Pitera DJ, Withers ST, Newman JD, Keasling JD, 2003. Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nat Biotechnol 21 : 796–802.
    [Google Scholar]
  11. Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, Ho KA, Eachus RA, Ham TS, Kirby J, Chang MC, Withers ST, Shiba Y, Sarpong R, Keasling JD, 2006. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440 : 940–943.
    [Google Scholar]
  12. Abdulla S, 2000. The Costs, Effects and Cost-Effectiveness of Changing the First Line Drug for the Treatment of Malaria in Tanzania. Ministry of Health, United Republic of Tanzania, and World Health Organization.
  13. Miller LH, Baruch DI, Marsh K, Doumbo OK, 2002. The pathogenic basis of malaria. Nature 415 : 673–679.
    [Google Scholar]
  14. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ, 2005. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2 : e100.
    [Google Scholar]

Data & Media loading...

  • Received : 21 Aug 2006
  • Accepted : 18 Oct 2006
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error